Guerbet's Financial Agenda
Guerbet, a leading player in medical imaging, has outlined its financial agenda for 2026, sharing crucial publication dates that reflect its commitment to transparency and growth. With a history built on innovation, this agenda marks another step in Guerbet's journey as it continues to enhance the quality of healthcare through advanced imaging solutions.
Key Publication Dates for 2026
The company has set several key dates in its calendar that will be of great interest to investors and stakeholders alike:
2025 Annual Revenue Report
Scheduled for February 5, 2026, after trading hours, this report will provide insights into Guerbet's revenue for the previous year, highlighting its performance and market positioning.
Annual Results
On March 11, 2026, Guerbet will release its annual results, allowing stakeholders to evaluate the fiscal year outcomes and strategic initiatives implemented throughout 2025.
First Quarter Revenue of 2026
Investors can expect the company's Q1 revenue report on April 23, 2026. This report will offer a glimpse into the company’s financial health and growth trajectory at the very start of the year.
Annual Shareholders' Meeting
This important meeting is slated for May 22, 2026. It will be a unique opportunity for shareholders to engage with management, discuss company direction, and vote on significant matters regarding the future of the company.
Innovation in Medical Imaging
For nearly a century, Guerbet has been at the forefront of medical imaging, innovating products that improve diagnostics and patient outcomes. The firm invests 9% of its revenue in R&D, underscoring a strong commitment to continuous improvement in its product offerings.
Quarterly Revenue Reports
In addition to the annual updates, Guerbet plans to share reports on its 2nd quarter revenue on July 23, 2026, and its 3rd quarter revenue on October 22, 2026. These reports will highlight the company's growth throughout the year and its market adaptability.
About Guerbet
Guerbet aims to forge lasting relationships to facilitate better living standards through its cutting-edge products and solutions in medical imaging. With a global workforce exceeding 2,900 employees, the company reflects its dedication to innovation at every level. In 2024, Guerbet recorded a remarkable revenue of €841 million, further solidifying its status in the industry. Its stock, GBT, is listed in compartment B of Euronext Paris, showcasing its stability and attractiveness to investors.
Company Contacts
Guerbet
Christine Allard, SVP Public Affairs and Corporate Communications
Contact: +33 6 30 11 57 82
Seitosei.Actifin
Marianne Py, Financial Communication
Contact: +33 6 85 52 76 93
Anne-Claire Taton, Press
Contact: +33 6 02 12 25 18
Frequently Asked Questions
What is Guerbet's business focus?
Guerbet specializes in medical imaging, providing contrast agents and solutions that enhance the quality of diagnostics.
When will Guerbet announce its annual revenue?
The announcement for the 2025 annual revenue will occur on February 5, 2026, after trading hours.
How much does Guerbet invest in research and development?
Guerbet commits 9% of its revenue to research and development to foster innovation in medical imaging.
Where is Guerbet's stock listed?
Guerbet is listed on Euronext Paris under the ticker symbol GBT.
What upcoming reports should investors look out for?
Investors should watch for reports on annual results, quarterly revenue updates, and the shareholders' meeting set for 2026.
